Rugby Labs' immediate-release diltiazem
Executive Summary
Rugby begins shipments Oct. 1 under an agreement with Cardizem maker Marion Merrell Dow ("The Pink Sheet" April 6, p. 3). Deal gives Rugby a jump on Mylan Labs, Copley Pharmaceuticals and Lederle; the three firms have received ANDA approvals for diltiazem, which become effective Nov. 5 following expiration of MMD's patent. The four dosage strengths of the Rugby diltiazem, which are being manufactured by MMD subsidiary Blue Ridge Labs, will be sold at an approximate 10% discount to the brandname product, according to Rugby.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth